[1] |
Thomas X. Acute promyelocytic leukemia: a history over 60 years-from the most malignant to the most curable form of acute leukemia[J]. Oncol Ther, 2019, 7(1): 33-65.
doi: 10.1007/s40487-018-0091-5
|
[2] |
Testi AM, D'Angiò M, Locatelli F, et al. Acute promyelocytic leukemia (APL): comparison between children and adults[J]. Mediterr J Hematol Infect Dis, 2014, 6(1): e2014032.
doi: 10.4084/mjhid.2014.032
|
[3] |
Jillella AP, Kota VK. The global problem of early deaths in acute promyelocytic leukemia: a strategy to decrease induction mortality in the most curable leukemia[J]. Blood Rev, 2018, 32(2): 89-95.
doi: S0268-960X(17)30025-5
pmid: 29033137
|
[4] |
中华医学会血液学分会, 中国医师协会血液科医师分会. 中国急性早幼粒细胞白血病诊疗指南(2018年版)[J]. 中华血液学杂志, 2018, 39(3): 179-183.
|
[5] |
Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracyclinedrags for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups[J]. Blood, 2000, 96(4): 1247-1253.
pmid: 10942364
|
[6] |
Gill H, Yung Y, Chu HT, et al. Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study[J]. Blood Adv, 2021, 5(14): 2829-2838.
doi: 10.1182/bloodadvances.2021004789
pmid: 34269798
|
[7] |
Abla O, Ribeiro RC, Testi AM, et al. Predictors of thrombo hemorrhagic early death in children and adolescents with t (15; 17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy[J]. Ann Hematol, 2017, 96 (9): 1449-1456.
doi: 10.1007/s00277-017-3042-6
|
[8] |
Dhakal P, Lyden E, Rajasurya V, et al. Early mortality and overall survival in acute promyelocytic leukemia: do real-world data match results of the clinical trials?[J]. Leuk Lymphoma, 2021, 62 (8): 1949-1957.
doi: 10.1080/10428194.2021.1894651
|
[9] |
Nasir SS, Giri S, Nunnery S, et al. Outcome of adolescents and young adults compared with pediatric patients withacute myeloid and promyelocytic leukemia[J]. Clin Lymphoma Myeloma Leuk, 2017, 17(2): 126-132.
doi: 10.1016/j.clml.2016.09.011
|
[10] |
de Azevedo AC, Matsuda E, Cervellini JY, et al. Early mortality in children and adolescents with acute promyelocytic leukemia: experience of the Boldrini children's center[J]. J Pediatr Hematol Oncol, 2020, 42(7): e641-e646.
doi: 10.1097/MPH.0000000000001601
|
[11] |
Sanz MA, Montesinos P. Advances in the management of coagulopathy in acute promyelocytic leukemia[J]. Thromb Res, 2020, 191(Suppl 1): S63-S67.
doi: 10.1016/S0049-3848(20)30399-6
|
[12] |
Mantha S, Goldman DA, Devlin SM, et al. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukaemia in the ATRA era[J]. Blood, 2017, 129(13): 1763-1767.
doi: 10.1182/blood-2016-10-747170
pmid: 28082441
|
[13] |
Baysal M, Gürsoy V, Hunutlu FC, et al. The evaluation of risk factors leading to early deaths in patients with acute promyelocytic leukemia: a retrospective study[J]. Ann Hematol, 2022, 101(5): 1049-1057.
doi: 10.1007/s00277-022-04798-8
pmid: 35190843
|
[14] |
Creutzig U, Zimmermann M, Dworzak M, et al. Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses[J]. Br J Haematol, 2010, 149(3): 399-409.
doi: 10.1111/bjh.2010.149.issue-3
|
[15] |
Zhang ZX, Lu AD, Wu J, et al. Retrospective analysis of data from 73 patients with childhood acute promyelocytic leukaemia receiving modified chemotherapy: a single-centre study[J]. J Cancer Res Clin Oncol, 2021, 147(4): 1189-1201.
doi: 10.1007/s00432-020-03406-4
|
[16] |
王静, 贾月萍, 刘桂兰, 等. 不同方案诱导治疗儿童急性早幼粒细胞白血病的临床分析[J]. 临床儿科杂志, 2014, 32(5): 405-409.
|
[17] |
张丽, 竺晓凡. 我如何治疗儿童急性早幼粒细胞白血病[J]. 中华血液学杂志, 2020, 41(10): 793-797.
|
[18] |
Hou J, Wang S, Zhang Y, et al. Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide[J]. Ann Hematol, 2017, 96(12): 2005-2013.
doi: 10.1007/s00277-017-3130-7
pmid: 28940056
|
[19] |
Ciftciler R, Haznedaroglu IC, Aksu S, et al. The factors affecting early death in newly diagnosed APL patients[J]. Open Med (Wars), 2019, 14: 647-652.
|
[20] |
Hou W, Zhang Y, Jin B, et al. Factors affecting thrombohemorrhagic early death in patients with acute promyelocytic leukemia treated with arsenic trioxide alone[J]. Blood Cells Mol Dis, 2019, 79: 102351.
doi: 10.1016/j.bcmd.2019.102351
|